L. Schwartz

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study.

P. Kantoff, P. Scardino, J. Eastham, 2004, The Journal of urology.

Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy.

M. Ladanyi, M. Kris, V. Rusch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D2-01: Prospective trial of preoperative gefitinib to correlate response with EGFR exon 19 and 21 mutations and to select patients for adjuvant gefitinib

M. Ladanyi, Binsheng Zhao, M. Kris, 2007 .

Role of transforming growth factor-beta in chronic lymphocytic leukemia.

S. Israels, J. Johnston, L. Israels, 1993, Leukemia research.

Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin).

S. Larson, H. Scher, N. Rosen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.

K. Brown, A. Covey, L. Brody, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Cytotoxic Treatment of Aggressive Prostate Tumors with or without Neuroendocrine Elements

V. Reuter, H. Scher, G. Steineck, 2002, Acta oncologica.

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

P. Kantoff, S. Larson, H. Scher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer

E. Venkatraman, D. Chi, P. Sabbatini, 2006, International Journal of Gynecologic Cancer.

Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer

M. Kris, N. Rizvi, L. Krug, 2007 .

The IFNs have been found to produce a large array of molecular and cellular actions of potential relevance to their use in cancer

S. Wadler, L. Schwartz, 2002 .